Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 July 2023 | Story André Damons | Photo Supplied
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), with his certificate after winning the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

A research paper by a Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS) has won the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

The abstract, by Dr Osayande Evbuomwan, was about evaluating the efficacy of a new nuclear medicine radiopharmaceutical in the identification of active disease in patients with rheumatoid arthritis. It was selected for this award by a special committee at the recently concluded SNMMI 2023 Annual Meeting, which took place between 24 and 27 June in Chicago, USA.

Dr Evbuomwan received the award at the Annual Meeting on 26 June.

“It is a good feeling, and I am proud of the UFS Department of Nuclear Medicine for pulling this off. It is another example that hard work pays,” he says.

Comparing this radiopharmaceutical to ultrasound

Dr Evbuomwan says the research that generated the award-winning abstract was aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. The study concluded that this particular radiopharmaceutical (Tc – 99m glucosamine) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints), and is capable of offering prognostic information in patients with rheumatoid arthritis.

This is the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says. He is currently working on comparisons of this radiopharmaceutical to ultrasound and clinical evaluation in the identification of active disease in patients with rheumatoid arthritis. He says there is also ongoing collaboration with the Rheumatology Division of the Internal Medicine Department, which has played a huge role in making this project fruitful.

“This award is an opportunity to put the department and university on the map, with world stage recognition. We believe that as the Nuclear Medicine Department continues to grow in human resources and equipment, the research output will also increase.”

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the whole department is very proud of Dr Evbuomwan’s accomplishments. “What makes his award even more remarkable is that he outperformed candidates from much larger, highly funded institutions,” he says.

This department announced last year the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

News Archive

Renowned Sign Language expert heads UFS department
2009-11-27

 Mr Philemon Akach

The Department of Afro-asiatic Studies, Sign Language and Language Practice in the Faculty of the Humanities at the University of the Free State recently appointed Mr Philemon Akach as its new chairperson.

Mr Akach, hitherto a senior lecturer in the department, succeeds Prof Annelie Lotriet who left the university earlier this year after having been elected to serve in the national parliament by the Democratic Alliance.

“To head the entire department has never crossed my mind because I think I am discipline oriented,” he said.

He said the confidence that his colleagues have in him gives him the impetus to succeed. “It gives me the opportunity to rethink my position within the department and the university at large,” he said.

However, his Sign Language students will be glad to know that he will not be lost to them as the result of this new responsibility.

“I cannot neglect Sign Language,” he stressed. “I have to teach because the academic side of Sign Language has to be maintained within the university, as well as nationally and internationally. I just have to divide my time between the administration of Sign Language and the teaching and research application in my discipline (Sign Language).”

To ease the load that comes with his new responsibility and the added pressure of being the only Sign Language lecturer, he said they have contracted former students to teach some courses in Sign Language.

“We have to keep in place the disciplines that keep this department’s name going,” he said.

A major challenge facing his department, according to Mr Akach, is getting more students enrolled in the disciplines offered by the department.

“To get students we need to convince them that we are the best, and that is not just a challenge for me but for the department and the lecturers in the department teaching those disciplines.”

He said he will strive for excellence in the department as part of the overall vision of the university.

“We need to get research output while not neglecting the teaching part. It is research that brings in new knowledge and it is through research that scholars expose themselves to the outside world, and by doing that they actually put the name of this university on the international map,” he said.

Mr Akach will serve in this position for the next three years.

Media release
Issued by: Mangaliso Radebe
Assistant Director: Media Liaison
Tel: 051 401 2828
Cell: 078 460 3320
E-mail: radebemt.stg@ufs.ac.za  
26 November 2009
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept